bioMérieux to Phase Out Microplate Immunoassay Production
in the United States
(Marcy-l'Etoile, France - December 19, 2006) – bioMérieux, a global leader in the field of in vitro diagnostics, today announced it will phase out production of microplate immunoassay business at its Durham, N.C. facility next year.
Click here
to read the press release
bioMérieux Sponsors Expert Discussion on the Impact of Medical Errors on the Hospital Community
Durham, NC (December 4, 2006) — Adverse drug events (ADEs) and medical errors are a cause of great concern in hospitals, causing more than 98,000 deaths each year, according to the Institute of Medicine’s report, “To Err is Human.”
Click here
to read the press release
bioMérieux Receives Prestigious Frost & Sullivan Award for NucliSENS® easyMAG™
DURHAM, NC (October 23, 2006) – bioMérieux, an industry-leading medical diagnostics company, has been selected by Frost & Sullivan to receive the 2006 North American Clinical Diagnostics Product Innovation of the Year award.
Click here
to read the press release
bioMérieux - 2006 Nine-Month Sales
MARCY L'ÉTOILE, FRANCE (October 19, 2006) – Up 6.1% - At constant exchange rates and scope of consolidation
Click here
to read the press release
Scientific Symposium: Procalcitonin – a Novel Marker for the Diagnosis of Respiratory Infections in the Emergency Department
DURHAM, NC (October 15, 2006) — In the constantly evolving field of emergency medicine, bioMérieux, a leading medical diagnostics company, announces plans to launch a new Procalcitonin (PCT) assay.
Click here
to read the press release
A Single D-Dimer Test Rules Out Risk of
DVT and PE in Moderate-Risk Patients
DURHAM, NC (October 15, 2006) — Recent statistics show an average of 200,000 deaths in the U.S. each year resulting from Pulmonary Embolism (PE), more than breast cancer and HIV combined.
Click here
to read the press release
First Automated Fluconazole MIC Susceptibility Test for Candida species Available from bioMérieux
DURHAM, NC (September 27, 2006) — bioMérieux, Inc. has received FDA 510(k) clearance for laboratories to perform fluconazole susceptibility tests on the VITEK® 2 automated microbiology system.
Click here
to read the press release
bioMérieux, Inc. Acquires Innovative Microbial Genotyping Technology
Durham, NC (September 18, 2006) – bioMérieux, a global leader in the field of in vitro diagnostics, has acquired Bacterial Barcodes, Inc. (BBCI), a molecular biotechnology company, based in Athens, Georgia.
Click here
to read the press release
First half 2006 results
MARCY L'ÉTOILE, FRANCE (September 18, 2006) – Sales up 6.1% (at constant exchange rates)
Click here
to read the press release
bioMérieux Selects Winners of “Innovation in Art” Contest
Durham, NC and St. Louis, MO (August 16, 2006) — bioMérieux, an industry-leading medical diagnostics company, recently announced the winners of its "Innovation in Art" contest, awarding more than $10,000 to college students and local university art departments.
Click here
to read the press release
MedAssets Supply Chain Systems Selects STELLARATM, Patient Therapy Management Software from bioMérieux to Broaden Offering of Innovative Medical Technology
Atlanta, GA and Durham, NC (August 14, 2006)— MedAssets Supply Chain Systems and bioMérieux, Inc. are pleased to announce the first group purchasing agreement for STELLARATM, clinical intervention and patient therapy management software, powered by TheraDoc® Expert System Platform®. Under the terms of the contract, STELLARA software will now be available to MedAssets Supply Chain Systems' comprehensive network of hospitals and healthcare providers. The multi-year agreement took effect June 15, 2006.
Click here
to read the press release
bioMérieux Announces Distribution Agreement with Cardinal Health
DURHAM, NC (August 3, 2006) - bioMérieux, Inc. is pleased to announce a new distribution agreement with Cardinal Health, a leading distributor serving the health care industry. Under terms of the new agreement, Cardinal Health will now have distribution rights to instruments and products within bioMérieux's immunoassay and nucleic acid diagnostic business. The agreement took effect January 1, 2006, and will continue for two and a half years.
Click here
to read the press release
bioMérieux VITEK® 2 Platform Receives Frost & Sullivan Award for Market Leadership
Durham, NC (July 27, 2006) — Frost and Sullivan, an industry leading global growth consulting company, is proud to present bioMérieux with the 2006 Award for Market Leadership for its VITEK® 2 and VITEK® 2 Compact infectious disease antibiotic susceptibility testing (ID/AST) platforms.
Click here
to read the press release
bioMérieux Releases Two New Real-Time NASBA® Analyte Specific Reagents for Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae
DURHAM, NC (July 25, 2006) - bioMérieux, a worldwide leader in the field of in vitro diagnostics, today announced the launch of analyte specific reagents (ASRs) for Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Click here
to read the press release
bioMérieux: Change in the Management Team
Marcy l'Etoile, France (July 10, 2006)- As part of the development of bioMérieux, Alain Mérieux, President, announced today the arrival of Stéphane Bancel in the bioMérieux management team. In the coming months, Stéphane Bancel will be working with Benoît Adelus, Executive Vice President, preparing to assume the management of bioMérieux in January 2007.
Click here
to read the press release
bioMérieux Launches 2nd Innovation in Motion Bus Tour at the American Society for Microbiology General Meeting in Orlando
(DURHAM, N.C., May 31, 2006) —Last week, bioMérieux, Inc., a world leader in the field of in vitro diagnostics, launched its Innovation in Motion tour, a high-tech bus-board presentation theater and mobile laboratory
Click
here to read the press release
bioMérieux
Sells its Hemostasis Line of Business
(Marcy-l'Etoile, France – May 25,
2006) – bioMérieux, a global leader in
the field of in vitro diagnostics, today announced that
it has signed an agreement to sell its hemostasis range
of products to Trinity Biotech plc.
Click
here to read the press release
bioMérieux
Launches ENQ® Intelligent Laboratory Interface
System to Resolve Connectivity Problems Between LIS and
Instruments
Durham, NC (May 22, 2006) — bioMérieux,
Inc. today introduces ENQ®, an advanced
multi-protocol laboratory interface management system
to easily resolve compatibility problems between bioMérieux
diagnostic instruments and hospital laboratory information
systems (LIS).
Click
here to read the press release
bioMérieux
Announces New Additions to the VITEK® 2
Test Card Portfolio
DURHAM, NC (May 22, 2006) — bioMérieux,
Inc. recently announced it has developed an Advanced
Colorimetry™ NH card for the VITEK® 2, which will provide an accurate, rapid and automated
method for the identification of Neisseria species,
Haemophilus species and other fastidious species.
Click
here to read the press release
bioMérieux
Recognizes Janet Hindler with Sonnenwirth Award
for Leadership in Clinical Microbiology
DURHAM, NC (May 22, 2006) — bioMérieux
is proud to present the 2006 Sonnenwirth Award for Leadership
in Clinical Microbiology to Ms. Janet A. Hindler.
Click
here to read the press release
bioMérieux
Announces Partnership with the Alliance for the Prudent
Use of Antibiotics (APUA®) to Further Research on
the Clinical and Financial Implications of Antibiotic
Resistance
DURHAM, NC (May 18, 2006) —
bioMérieux, a leading international diagnostics
company, announced an agreement with the Alliance for
the Prudent Use of Antibiotics (APUA®), a non-profit,
international organization dedicated to promoting appropriate
antibiotic access and use and curbing antibiotic resistance
worldwide.
Click
here to read the press release
bioMérieux
demonstrates innovation@work during Annual American Society
for Microbiology General Meeting
DURHAM, NC (May 18, 2006) — bioMérieux,
Inc., a market leader in the field of microbiology diagnostics,
will introduce new products and host a number of educational
and social events during the 106th American Society
for Microbiology (ASM) General Meeting next week in
Orlando, Florida.
Click
here to read the press release
bioMérieux
Introduces Organism Surveillance Network to Identify and
Control Emerging Infectious Disease Threats
Durham, NC (May 17, 2006) — In an
effort to combat emerging disease threats, bioMérieux,
a leading international diagnostics company, announces
the launch of an innovative system to collect organisms
exhibiting unusual antimicrobial resistance mechanisms.
Click
here to read the press release
bioMérieux
NucliSENS® easyMAG™ Receives Technology Innovation
of the Year Award from Frost & Sullivan
DURHAM, NC (April 25, 2006) — bioMérieux
has been the proud recipient of 2006 Technology Innovation
of the Year award in the field of in vitro diagnostics.
Click here
to read the press release
ExonHit and bioMérieux
reach an important research milestone in the molecular
detection of breast cancer from blood samples
Marcy l’Etoile and Paris, France
– 29 March 2006. ExonHit Therapeutics, a French
drug and diagnostic discovery company, and bioMérieux,
a major player in the field of in vitro diagnostics,
announce today that they have reached an important research
milestone in the diagnosis of breast cancer.
Click here to
read the press release
bioMérieux
Seeks Creative Work from College Students in North
Carolina and Missouri for ‘Innovation in Art’
Contest
Durham, NC and St. Louis, MO (March 28,
2006) — bioMérieux, a-leading international
diagnostics group, has built its reputation on innovation,
creativity and the pursuit of knowledge.
Click
here to read the press release
bioMérieux
Announces 2005 Financial Results
(MARCY-L'ÉTOILE, FRANCE –
MARCH 20, 2006) — The Board of Directors of bioMérieux
met on Friday, March 17 to approve the consolidated
financial statements for the year ended December 31,
2005.
Click
here to read the press release
STELLARA™
Demonstrates Significant Cost Savings and Reduction of
Adverse Drug Events at Franciscan Health System
Durham, NC (February 13, 2006) —
bioMérieux, Inc. recently announced the one-year
anniversary for STELLARA™ Clinical Intervention
and Patient Monitoring software, powered by TheraDoc® Expert System Platform®.
Click
here to read the press release
View
2005 Press Releases
View
2004 Press Releases
View 2003 Press Releases
View 2002 Press Releases
View 2001 Press Releases
|
